Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
In a Phase 2 subgroup of mild-to-moderate Alzheimer’s disease, zervimesine (CT1812) was associated with a 95% slowing of cognitive...
Vaxil Announces Update on Non-Brokered Private Placement
Vaxil Bio revised a planned financing to raise up to $350,000 via a non-brokered private placement of 3,111,111 units...
Junshi’s JS001SC Meets Phase 3 Endpoints for Lung Cancer
Non-squamous NSCLC patients treated first line with subcutaneous toripalimab plus chemotherapy achieved non-inferior drug exposure to intravenous toripalimab plus...
Praxis Reveals New Epilepsy Portfolio Data at AES Meeting
Praxis is taking a late-breaker slot at AES 2025 to unveil full results from RADIANT, reporting rapid seizure reductions...
Clearmind Trial Gets Unanimous Approval After Safety Review
Topline from the first dosing cohort: no serious adverse events, generally good tolerability, and strong protocol adherence. An independent...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule
Climb Bio granted a non-statutory option covering 120,000 shares at an exercise price of $1.76 to a single new...
NCCN Adds Ziftomenib to Acute Myeloid Leukemia Guidelines
Komet-001 reported a 21.4% CR/CRh rate with a median duration of response of five months in adults with relapsed...
BioMX Provides Important Update on BX004 CF Phase 2b Trial
An independent data monitoring committee for BiomX’s Phase 2b BX004 trial in cystic fibrosis recommended the study continue with...
CG Oncology to Present Cretostimogene Results at SUO Meeting
No efficacy or safety figures were disclosed ahead of the meeting. CG Oncology signaled that topline data from the...
Profound Medical Unveils AI BPH Module, New Clinical Data
Perioperative data from the CAPTAIN randomized trial indicated lower blood loss, shorter length of stay, reduced post‑operative pain, and...